Nobiletin ameliorates cardiac impairment and alleviates cardiac remodeling after acute myocardial infarction in rats via JNK regulation

• Published in: Pharmacology research & perspectives Vol. 9; no. 2; pp. e00728 - n/a
• Main Authors: Liu, Zumei, Gao, Zhimin, Zeng, Lihuan, Liang, Zhenye, Zheng, Dechong, Wu, Xiaoqian
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2021; John Wiley and Sons Inc; Wiley
• Subjects: acute myocardial infarction; Animals; Apoptosis; Apoptosis - drug effects; Autophagy; cardiac remodeling; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cell Line; Coronary vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Flavones - pharmacology; Flavones - therapeutic use; Gene expression; Glucose; Heart attacks; Humans; hypertrophy; Ischemia; JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors; JNK Mitogen-Activated Protein Kinases - metabolism; Kinases; Laboratory animals; Male; MAP Kinase Signaling System - drug effects; Medical research; Myoblasts - drug effects; Myoblasts - pathology; Myocardial Infarction - complications; Myocardial Infarction - drug therapy; Myocardial Infarction - pathology; Myocardium - cytology; Myocardium - pathology; nobiletin; Original; Ostomy; Pharmacology; Phosphorylation; Proteins; Rats; Ventricular Remodeling - drug effects; apoptosis; nobiletin; hypertrophy; acute myocardial infarction; cardiac remodeling

Nobiletin was found to protect against acute myocardial infarction (AMI)‐induced cardiac function decline and myocardial remodeling, although the dose–effect relationship and underlying pathways remained unclear. In the current research, different doses of Nobiletin (7.5, 15 and 30 mg/kg/day) were a...